Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer

A third of patients with triple negative breast cancer (TNBC) have relapsed disease within 2–5 years from initial diagnosis, leaving an unmet need for therapeutic targets. TNBC frequently harbors alterations of the PI3K/AKT/mTOR pathway, but single agent PI3K/AKT/mTOR inhibitors have not shown marke...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yuan, Wen, Wei, Yost, Susan E., Xing, Quanhua, Yan, Jin, Han, Ernest S., Mortimer, Joanne, Yim, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525251/
https://www.ncbi.nlm.nih.gov/pubmed/31101835
http://dx.doi.org/10.1038/s41598-019-43429-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525251/
https://www.ncbi.nlm.nih.gov/pubmed/31101835
http://dx.doi.org/10.1038/s41598-019-43429-7

Ejemplares similares